STOCK TITAN

Health In Tech adds CEO Sanjay Shrestha, 2 others to board

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Health In Tech, Inc. (HIT) reported that stockholders elected Tim Cortes to its Board effective November 10, 2026, and the Board appointed CEO Sanjay Shrestha and Christina R. Valauri effective November 12, 2026. Each will serve a one-year term, until a successor is duly elected and qualified or an earlier death, resignation, disqualification or removal.

Cortes and Valauri are independent directors. Cortes chairs the Compensation Committee and serves on the Audit and Nominating and Corporate Governance Committees; Valauri serves on all three. Both became eligible for compensation under the non-employee director compensation policy. Health In Tech intends to enter into indemnification agreements with each, providing contractual rights to indemnification, expense advancement and reimbursement to the fullest extent permitted under Nevada law, subject to exceptions in the agreements.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cortes election effective date November 10, 2026 Stockholders elected him to the Board.
Shrestha and Valauri appointments effective date November 12, 2026 The Board appointed them as directors.
Board term 1 year Each director serves until a successor is duly elected and qualified or an earlier end to service.
indemnification agreement regulatory
"intends to enter into an indemnification agreement with each party"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
non-employee director compensation policy financial
"eligible to receive compensation in accordance with the Company’s non-employee director compensation policy"
AI-enabled underwriting technical
"AI-enabled underwriting"
stop-loss quotes financial
"bindable stop-loss quotes"
Managing General Underwriter technical
"Managing General Underwriter (“MGUs”)"
The managing general underwriter is the lead investment bank or financial firm that organizes and runs a securities offering, coordinating other banks, setting the initial price range, handling paperwork and marketing, and allocating shares to buyers. For investors, this role matters because the manager shapes how widely an offering is distributed, how aggressively it is priced and marketed, and how risks are shared—similar to a project captain whose choices influence whether a new issue sells smoothly and at a fair price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did HIT's new directors join the board?

Tim Cortes's election was effective November 10, 2026; Sanjay Shrestha's and Christina R. Valauri's appointments were effective November 12, 2026. Each will serve a one-year term, until a successor is duly elected and qualified or an earlier death, resignation, disqualification or removal.

What committees will HIT directors Cortes and Valauri serve on?

Cortes chairs the Compensation Committee and serves on the Audit and Nominating and Corporate Governance Committees. Valauri serves on the Audit, Compensation, and Nominating and Corporate Governance Committees.

What do HIT's planned indemnification agreements cover?

Health In Tech intends to enter into agreements with Cortes and Valauri that provide contractual rights to indemnification, expense advancement and reimbursement to the fullest extent permitted under Nevada law, subject to exceptions in the agreements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0002019505 0002019505 2026-11-17 2026-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

November 17, 2026

Date of Report (Date of earliest event reported)

 

Health In Tech, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-42449   87-3545722
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

701 S. Colorado Ave, Suite 1
Stuart, FL
  34994
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 373-0333

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, $0.001 par value per share   HIT   The Nasdaq Stock Market LLC
(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As previously disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 12, 2026 and in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 filed with the SEC on November 13, 2026, respectively, the stockholders of Health In Tech, Inc., a Nevada corporation (the “Company”), elected Tim Cortes, age 60, to the Company’s Board of Directors (the “Board”), effective as of November 10, 2026, and the Board appointed the Chief Executive Officer of the Company, Sanjay Shrestha, age 52, and Christina R. Valauri, age 71, to the Board, in each case effective as of November 12, 2026. Mr. Shrestha, Mr. Cortes and Ms. Valauri will each serve as a member of the Board for a one-year term and until a successor is duly elected and qualified or until his or her earlier death, resignation, disqualification, or removal. There are no arrangements or understandings between any of Mr. Shrestha, Mr. Cortes or Ms. Valauri and the Company or any other person pursuant to which he or she was selected as a director. The Board has appointed Mr. Cortes, as an independent director, to the Audit Committee, to the Nominating and Corporate Governance Committee and as Chair of the Compensation Committee of the Board. The Board has also appointed Ms. Valauri, as an independent director, to serve on the Audit Committee, the Nominating and Corporate Governance Committee and the Compensation Committee of the Board. There are no related party transactions involving Mr. Shrestha, Mr. Cortes or Ms. Valauri that would require disclosure under Item 404(a) of Regulation S-K.

 

Effective upon their respective appointments, Mr. Cortes and Ms. Valauri each became eligible to receive compensation in accordance with the Company’s non-employee director compensation policy which was described in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026. In connection with each of Mr. Cortes’ and Ms. Valauri’s selection as a director of the Board, the Company intends to enter into an indemnification agreement with each party in the same form as the indemnification agreements the Company has entered into with its other directors and officers. The indemnification agreements provide the Company’s executive officers and directors with contractual rights to indemnification, expense advancement and reimbursement, to the fullest extent permitted under Nevada law, subject to certain exceptions contained in those agreements. There are no other material plans, contracts or arrangements to which either of Mr. Cortes or Ms. Valauri is a party or in which he or she participates that was entered into in connection with his or her selection as a director of the Board.

 

Item 7.01 Regulation FD Disclosure.

 

On November 17, 2026 and November 18, 2026, respectively, the Company issued a press release announcing the appointment of Ms. Valauri to the Board and a press release announcing the election of Mr. Cortes to the Board. A copy of the press release relating to Ms. Valauri’s appointment is furnished as Exhibit 99.1 to this Current Report on Form 8-K and a copy of the press release relating to Mr. Cortes’ election is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 and Exhibit 99.2 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.   Description
99.1   Press Release, dated November 17, 2026.
99.2   Press Release, dated November 18, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 18, 2026  
   
HEALTH IN TECH, INC.  
     
By: /s/ Julia (LinLin) Qian  
Name: Julia (LinLin) Qian  
Title: Chief Financial Officer  

 

2

 

Exhibit 99.1

 

Health In Tech Appoints Wall Street Research and Capital Markets Veteran Christina R. Valauri to Board of Directors

 

Seasoned public company director and senior capital markets executive brings more than 30 years of financial services leadership, corporate governance and strategic advisory experience, includes senior roles at Cantor Fitzgerald, Natixis, ING Barings and Crédit Lyonnais

 

STUART, Fla., November 17, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) (“Health In Tech” or the “Company”), an AI-enabled InsurTech platform company, today announced the appointment of Christina R. Valauri to its Board of Directors as an independent director, effective November 12, 2026. Ms. Valauri will serve as a member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee of the Board.

 

Ms. Valauri brings more than three decades of Wall Street and capital markets analytical, management and leadership experience, having held Managing Director and senior executive positions at prominent global financial institutions, including Cantor Fitzgerald, Natixis, ING Barings and Crédit Lyonnais. Her leadership roles included Global Director of Equity Research at Cantor Fitzgerald and Co-Head of Equity Capital Markets at First Albany where she also served on the firm’s operating committee. Throughout her career, she has led global research organizations, driven strategic business transformation and established regulatory and supervisory frameworks. A recognized healthcare investment research professional, Ms. Valauri was ranked No. 1 in the biomedical and biotechnology sector in The Wall Street Journal’s “Best on the Street” All-Star Analyst Survey.

 

Sanjay Shrestha, Chief Executive Officer of Health In Tech, commented:

 

“Christina brings a valuable combination of Wall Street leadership, healthcare industry insight and public company governance experience,” said Sanjay Shrestha, Chief Executive Officer of Health In Tech. “She understands how institutional investors evaluate management teams, business models, competitive positioning and the ability to translate innovation into sustainable growth. Her experience advising emerging healthcare companies also brings a practical perspective on commercialization and the organizational capabilities needed to scale. As we expand our AI-enabled marketplace, strengthen our distribution relationships and advance our product portfolio, we believe Christina’s insights will help our Board evaluate strategic opportunities, support disciplined execution and guide the Company toward long-term shareholder value creation.”

 

 

 

 

Throughout her career, Ms. Valauri has led international equity research teams across New York, London, Hong Kong and Toronto, built and managed institutional research organizations and implemented business transformation initiatives. She also brings substantial experience in corporate governance, regulatory oversight and risk management. As a senior research executive and broker-dealer manager, she established regulatory and supervisory frameworks designed to uphold SEC and FINRA requirements and corporate governance best practices.

 

Ms. Valauri spent more than 16 years as a senior sell-side equity research analyst covering pharmaceutical, biotechnology and medical technology companies in the U.S. and internationally, including at PaineWebber. Her analytical experience encompasses evaluating emerging healthcare technologies, assessing business models and competitive dynamics, and identifying commercial opportunities and investment considerations. This research background, combined with her understanding of institutional investor expectations, provides valuable insight into the opportunities and challenges facing technology-driven healthcare companies.

 

Ms. Valauri currently serves as an independent director of two other Nasdaq-listed companies, Valion Bio, Inc. (Nasdaq: VBIO) since July 2024 and Precipio, Inc. (Nasdaq: PRPO) since January 2024, bringing additional public company governance experience to our Board. She is also the Founder and CEO of Sagestone Advisory LLC, where she advises emerging companies on business strategy, capital markets positioning and growth initiatives. Additionally, she serves as a Mentor and Guest Lecturer at Weill Cornell Medicine’s BioVenture eLab, where she previously served as Entrepreneur in Residence, supporting the development and commercialization of innovative healthcare technologies.

 

Ms. Valauri holds an Executive MBA from Cornell University and a Bachelor of Arts in Biology from Reed College. She is also a National Association of Corporate Directors (NACD) Certified Director.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Health In Tech, Inc.’s (“Health In Tech,” “we,” “us” or “our”) business strategy, product development and innovation, growth prospects, and future operating and financial performance. In some cases, forward-looking statements can be identified by terminology such as “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target” or similar expressions that are predictions of or indicate future events or trends and that do not relate solely to historical matters. Forward-looking statements in this press release include, but are not limited to, statements regarding the expected benefits of the Company’s leadership transition; the Company’s strategic priorities, including accelerating organic growth and commercial execution, expanding adoption of its solutions and strengthening distribution and carrier partnerships; the Company’s intention to evaluate and pursue potential acquisitions, strategic investments, partnerships and other business opportunities; and the Company’s ability to create long-term shareholder value.

 

2

 

 

These forward-looking statements are based on current expectations and beliefs concerning future events and developments and their potential effects on Health In Tech and are subject to numerous known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Health In Tech’s control, that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These factors include, but are not limited to: risks related to the leadership transition, including our ability to successfully integrate new management and retain key personnel; our ability to identify, negotiate, finance, complete and integrate acquisitions or other strategic transactions on favorable terms, or at all; our ability to obtain funding for our operations and to enhance our current systems and expand our service offerings; our ability to regain and maintain compliance with The Nasdaq Stock Market LLC continued listing requirements; the success, cost and timing of our product development activities; our ability to attract and retain key personnel and qualified employees; our ability to attract new customers and to develop new, and enhance existing, products and services; the impact of competition in our industry and innovation by our competitors; risks related to cybersecurity incidents or other network disruptions; risks related to the use of third-party artificial intelligence; our ability to comply with new or modified laws and regulations applicable to our business, including with respect to the insurance services industry and data privacy requirements; our ability to protect our intellectual property rights and maintain and build our brand; the future trading price of our common stock; and other risks and uncertainties described in the “Risk Factors” section of our most recent Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission.

 

Any forward-looking statement made in this press release speaks only as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible for Health In Tech to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release. Except as required by applicable law, Health In Tech does not undertake, and expressly disclaims, any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

 

About Health In Tech

 

Health In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriter (“MGUs”) and third-party administrators (“TPAs”). Health In Tech’s platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.

 

Investor Contact:

 

Health In Tech Investor Relations

ir@healthintech.com

 

3

 

Exhibit 99.2

 

Health In Tech Appoints Tim Cortes as Independent Director, Chair of the Compensation Committee

 

Technology veteran brings more than 30 years of experience in technology innovation, clean energy, power systems, and product development to support Health In Tech’s AI strategy and product innovation initiatives.

 

STUART, Fla. — November 18, 2026 — Health In Tech, Inc. (Nasdaq: HIT) (“Health In Tech” or the “Company”), an AI-enabled InsurTech platform company, today announced that Tim Cortes has joined the Company’s Board of Directors as an independent director. In connection with his election to the Board, Mr. Cortes has also been appointed Chair of the Board’s Compensation Committee, as a member of the Audit Committee and as a member of the Nominating and Corporate Governance Committee.

 

Mr. Cortes brings more than three decades of experience as a visionary technology and innovation leader, with extensive expertise spanning clean energy, power systems, advanced technology development, and product innovation. Throughout his career, he has focused on developing and commercializing technology solutions, leading product development initiatives, and helping organizations navigate complex technology transformations.

 

His experience in technology strategy, innovation, engineering, and product development is expected to bring valuable perspective to Health In Tech as the Company accelerates its AI initiatives, advances its technology infrastructure, expands its product portfolio, and pursues new opportunities to transform the self-funded healthcare insurance marketplace.

 

As Health In Tech continues to invest in artificial intelligence, automation, data-driven solutions, and next-generation insurance technology, Mr. Cortes’s experience in bringing innovative technologies from concept through product development and commercialization is expected to complement the Company’s strategic priorities. His background will provide an additional perspective as the Company evaluates new AI applications, develops new products, and pursues opportunities to improve efficiency and create greater value for brokers, third-party administrators, managing general underwriters, carriers, and employers.

 

As Chair of the Compensation Committee, Mr. Cortes will also contribute to the Board’s oversight of executive compensation strategy, leadership development, and alignment of management incentives with the Company’s long-term objectives and shareholder interests.

 

“We are very pleased to welcome Tim Cortes to Health In Tech’s Board of Directors,” said Sanjay Shrestha, Chief Executive Officer of Health In Tech. “Tim brings more than 30 years of technology and innovation leadership, with a particularly strong background in clean energy, power systems, and product development. As we enter our next phase of growth, we are focused on leveraging artificial intelligence across our business, accelerating our innovation initiatives, and bringing new technology-driven products and solutions to market. We believe Tim’s experience in developing and commercializing innovative technologies will be extremely valuable as we execute on these priorities. We also look forward to benefiting from his leadership as Chair of our Compensation Committee as we continue to strengthen corporate governance and align our leadership team around long-term shareholder value creation.”

 

The appointment reflects Health In Tech’s continued commitment to strengthening its Board with experienced independent leaders who bring complementary expertise in technology, innovation, corporate governance, and strategic growth.

 

 

 

About Health In Tech

 

Health In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, managing general underwriters (“MGUs”) and third-party administrators (“TPAs”). Health In Tech’s platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Health In Tech, Inc.’s (“Health In Tech,” “we,” “us” or “our”) business strategy, product development and innovation, growth prospects, and future operating and financial performance. In some cases, forward-looking statements can be identified by terminology such as “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” “objective” or similar expressions that are predictions of or indicate future events or trends and that do not relate solely to historical matters. Forward-looking statements in this press release include, but are not limited to, statements regarding the expected benefits of the Company’s leadership transition; the Company’s strategic priorities, including accelerating organic growth and commercial execution, expanding adoption of its solutions, leveraging artificial intelligence and strengthening distribution and carrier partnerships; the Company’s intention to evaluate and pursue potential acquisitions, strategic investments, partnerships and other business opportunities; and the Company’s ability to create long-term shareholder value.

 

These forward-looking statements are based on current expectations and beliefs concerning future events and developments and their potential effects on Health In Tech and are subject to numerous known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Health In Tech’s control, that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These factors include, but are not limited to: risks related to the leadership transition, including our ability to successfully integrate new management and retain key personnel; our ability to identify, negotiate, finance, complete and integrate acquisitions or other strategic transactions on favorable terms, or at all; our ability to obtain funding for our operations and to enhance our current systems and expand our service offerings; our ability to regain and maintain compliance with The Nasdaq Stock Market LLC continued listing requirements; the success, cost and timing of our product development activities; our ability to attract and retain key personnel and qualified employees; our ability to attract new customers and to develop new, and enhance existing, products and services; the impact of competition in our industry and innovation by our competitors; risks related to cybersecurity incidents or other network disruptions; risks related to the use of third-party artificial intelligence; our ability to comply with new or modified laws and regulations applicable to our business, including with respect to the insurance services industry and data privacy requirements; our ability to protect our intellectual property rights and maintain and build our brand; the future trading price of our common stock; and other risks and uncertainties described in the “Risk Factors” section of our most recent Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission.

 

Any forward-looking statement made in this press release speaks only as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible for Health In Tech to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release. Except as required by applicable law, Health In Tech does not undertake, and expressly disclaims, any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

 

Investor Contact:

 

Health In Tech Investor Relations

ir@healthintech.com

 

 

 

Filing Exhibits & Attachments

5 documents

Keep reading